Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Fill me in guys. What is your 3 month target?
Somebody named Zincfingers told KBLB shareholders about this stock--glad i bot some.
Zinc if u r out there thanks and come visit the KB board sometime.
If just started to follow it.
Do you like this stock?
Third Quarter 2017 Financial Results
For the third quarter ended September 30, 2017, Sangamo reported a consolidated net loss of $12.4 million, or $0.15 per share, compared to a net loss of $19.0 million, or $0.27 per share, for the same period in 2016.
As of September 30, 2017, the Company had cash, cash equivalents, marketable securities and interest receivable of $253.5 million
This is HUGE for both patients and the company!
https://www.yahoo.com/news/us-scientists-try-first-gene-060926736.html
Sanp along side another huge upside play frlf about to both have a nice bounce
BioSciences logoSangamo BioSciences Inc. (NASDAQ:SGMO) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 7,636,100 shares, a decrease of 12.2% from the August 31st total of 8,693,947 shares. Currently, 11.1%
https://sheridandaily.com/the-street-expecting-0-23-per-share-for-sangamo-therapeutics-inc-nasdaqsgmo/347791/
Zacks provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) currently has an ABR of 1.67 heading into today’s announcement. This ABR has an industry rank of 173. This number is also based on the 6 sell-side firms polled by Zacks. Analysts on a consensus basis are expecting that the stock will reach $16.75 within the year.
$SGMO is currently rated a HOLD and long term is a BUY. Earnings are at close today.
Is this accurate? I cannot seem to find it. I like this tid bit.
Traders may be relying in part on technical stock analysis. Sangamo Therapeutics (SGMO) currently has a 14-day Commodity Channel Index (CCI) of -143.65. Despite the name, CCI can be used on other investment tools such as stocks. The CCI was designed to typically stay within the reading of -100 to +100. Traders may use the indicator to determine stock trends or to identify overbought/oversold conditions. A CCI reading above +100 would imply that the stock is overbought and possibly ready for a correction. On the other hand, a reading of -100 would imply that the stock is oversold and possibly set for a rally.
Good sign today. Day before earnings.
I added yesterday, and many other occasions during the pull back this week. We may see a 13 price print before the decline stops, but we could see 18 or higher on any news. It is not worth the risk of missing out on a large price increase just to buy a point lower.
Way over sold at this time. Even with the terrific returns year to date. Healthy pull back and a beat on earnings could trigger that 8.9% short frenzy.
https://kaplanherald.com/2017/10/18/sangamo-therapeutics-sgmo-ppo-reading-below-the-signal-line-on-this-stock/
Sangamo Therapeutics is involved in the quickly growing field of genome editing, but with a twist
https://www.clinicalleader.com/doc/in-genome-editing-trials-the-effects-last-a-lifetime-0001?sthash.QAS2HPmw.mjjo
Go $SGMO! 100K+ shares purchased at 10:39 am, pushing the stock over the $16 mark.
Wow, just wow!
This was the cover story on Barron's two weekends ago.
Stock was $12.90 on the Friday before the Barron's article. This past Friday's close was $15.00, and there is good News this morning.
Go $SGMO!!!
With today's news, $SGMO has 6 approved Phase 1/2 FDA trials:
Hemophilia A
Hemophilia B
MPS I (Scheie, Hurler-Scheie and Hurler syndromes)
MPS II (Hunter syndrome)
Beta thalassemia
HIV (TCells)
HIV (HSCs)
RICHMOND, Calif. and WALTHAM, Mass., Oct. 2, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, and Bioverativ Inc. (NASDAQ: BIVV), a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. Sangamo and Bioverativ are developing ST-400 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for beta-thalassemia and sickle cell disease.
"We are very pleased with the FDA's acceptance of the IND for ST-400 for the treatment of beta-thalassemia and look forward to initiating the first clinical trial," said Edward Conner, M.D., chief medical officer at Sangamo. "We believe the precision, efficiency and specificity of zinc finger nuclease gene editing technology will differentiate ST-400 among other genomic therapies in development for beta-thalassemia."
"Beta-thalassemia is a serious, lifelong blood disorder, and many children and adults with the disease require frequent and demanding blood transfusions that may lead to iron overload and long-term organ damage," said Tim Harris, Ph.D., D.Sc., executive vice president of research and development at Bioverativ. "The advancement of ST-400 demonstrates our commitment to progressing novel science that has the potential to make a meaningful, lasting difference in the lives of people with beta-thalassemia."
The IND enables Sangamo to initiate a Phase 1/2 clinical trial to assess the safety, tolerability and efficacy of ST-400 in adults with transfusion-dependent beta-thalassemia. Sangamo expects to open several clinical sites across the United States and begin enrolling patients in the first half of 2018.
Beta-thalassemia is an inherited blood disorder caused by mutations in the beta-globin gene that leads to reduced or absent production of adult hemoglobin, the protein in red blood cells that carries oxygen to cells throughout the body. The disorder causes the destruction of red blood cells, which results in severe anemia and reduced oxygen transport to various tissues in the body.
According to the World Health Organization, there are approximately 100,000 treated beta-thalassemia patients worldwide, with ~19,000 of those in the United States and Europe.1 The majority of these patients are transfusion-dependent, and their current standard of care includes a chronic regimen of red blood cell transfusions, which may lead to iron overload and organ damage even with daily iron chelation therapy. Allogeneic bone marrow transplant may be a treatment option for these patients if a suitable donor can be found, but carries substantial risks such as graft-versus-host disease and chronic morbidity.
About ST-400 and the Phase 1/2 Clinical Trial
ST-400 is an autologous cell therapy that involves gene editing of a patient's own hematopoietic stem cells (HSCs) using zinc finger nuclease (ZFN) technology. It is being developed with the aim of providing a one-time treatment for people with transfusion-dependent beta-thalassemia by increasing production of fetal hemoglobin, which can more effectively carry oxygen, potentially eliminating the need for chronic blood transfusions. As part of the Phase 1/2 clinical trial protocol, a patient's HSCs are isolated from the blood, and the cells then undergo ex-vivo gene editing using ZFNs to modify a specific sequence of the BCL11A gene that suppresses fetal hemoglobin production in erythrocytes. Following a conditioning regimen, patients will be infused with their own modified HSCs, with the goal of producing increased amounts of fetal hemoglobin to compensate for the decrease in functional beta-globin levels, potentially resolving the need for chronic blood transfusions and ameliorating the complications from major organ failure that frequently arise from the disease.
About the Sangamo and Bioverativ collaboration
Sangamo and Bioverativ have an exclusive worldwide collaboration to develop and commercialize ZFN-mediated gene-edited cell therapies for the treatment of beta-thalassemia and sickle cell disease. Based on the terms of the agreement, Sangamo is responsible for conducting the ST-400 Phase 1/2 clinical trial, and Bioverativ will be responsible for subsequent worldwide clinical development, manufacturing, and commercialization.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ Inc. for hemoglobinopathies, including beta-thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at www.sangamo.com.
About Bioverativ
Bioverativ is a global biopharmaceutical company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company's mission is to create progress for patients where they need it most and its hemophilia therapies when launched represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit bioverativ.com or follow @bioverativ on Twitter.
Sangamo's Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the therapeutic potential of gene editing and ST-400, including the potential of ST-400 as a one-time treatment option for people with beta-thalassemia, the planned Phase 1/2 clinical trial of ST-400, including its design and Sangamo's expectations for opening clinical sites and enrolling patients and the timing thereof, as well as other statements that are not historical facts. These forward-looking statements are based on Sangamo's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: gene therapy product candidate development and the inherent uncertainty of clinical success, including the risks that Sangamo and/or Bioverativ may encounter unanticipated toxicity or adverse events in, or fail to demonstrate the efficacy of ST-400 in, clinical development and that the planned Phase 1/2 clinical trial may otherwise fail to validate and support the tolerability and efficacy of ST-400; Sangamo's substantial dependence on the clinical success of its lead therapeutic programs; the initiation, enrollment and completion of the stages of its clinical trials, including Sangamo's potential inability to enroll the planned Phase 1/2 clinical trial of ST-400 in a timely manner or at all; technological challenges; the lengthy and uncertain regulatory approval process; Sangamo's and Bioverativ's ability to develop a commercially viable ST-400 product or other products under the collaboration; technological developments by competitors and others in the genomic therapy field; and Sangamo's dependence on its collaboration with Bioverativ for the development of ST-400 and its ability to maintain its collaboration with Bioverativ. A more detailed discussion of these and other risks and uncertainties may be found under the caption "Risk Factors" and elsewhere in Sangamo's SEC filings and reports, including Sangamo's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 and future filings and reports by Sangamo. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
Bioverativ Safe Harbor
This press release contains forward-looking statements, including statements about the potential benefits, safety and effects of ST-400, and expected timing and enrollment of clinical trials. These statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on Bioverativ's current beliefs and expectations. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Factors which could cause actual results to differ materially from Bioverativ's current expectations include: uncertainties relating to the initiation, enrollment and completion of stages of clinical trials; unexpected concerns may arise from data, analysis or results obtained during clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of product candidates; risks and uncertainties relating to collaborations; Bioverativ's reliance on third parties over which it may not have control; or Bioverativ may encounter other unexpected hurdles. For more detailed information on the risks and uncertainties associated with Bioverativ's drug development and commercialization activities, please review the Risk Factors section of Bioverativ's most recent annual or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and Bioverativ assumes no obligation to update any forward-looking statements.
References
1World Health Organization. Global Epidemiology of Haemoglobin Disorders and Derived Service Indicators. Available at: www.who.int/bulletin/volumes/86/6/06-036673-table-T3.html. Accessed on: September 28, 2017.
8 Stocks for the Next Gene Revolution
http://www.investopedia.com/news/8-stocks-next-gene-revolution/
BarChart showing $SGMO as a 96% Strong Buy
https://www.barchart.com/stocks/quotes/SGMO
$SGMO hitting the investor circuits hard, first Cantor Fitzgerald and now
"RICHMOND, Calif., Sept. 28, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's chief executive officer, will participate in the following conferences in October.
2017 Cell & Gene Meeting on the Mesa, La Jolla, CA, October 4-6, 2017
Dr. Macrae will participate in a panel discussion on gene editing at 9:15 a.m. PT on Thursday, October 5th, and is scheduled to present a company overview later that afternoon during the annual Partnering Forum at 2:15 p.m. PT.
Jefferies Gene Technology Investor Summit, New York, NY, October 12, 2017
Dr. Macrae is scheduled to present a company overview at 2:50 p.m. ET on Tuesday, October 12th.
The presentations will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A replay of the presentations will be archived on the Sangamo website for two weeks after the event."
$SGMO presenting to the Cantor Fitzgerald Global Healthcare Conference TODAY.
IF you have Flash installed you can see the webcast and deck: http://investor.sangamo.com/events/detail/1403/2017-cantor-fitzgerald-global-healthcare-conference
For Hemophilia A, $SGMO has a partnership with $PFE:
Sangamo Therapeutics And Pfizer Announce That SB-525 Investigational Hemophilia A Gene Therapy Receives Orphan Medicinal Product Designation From The European Medicines Agency
http://investor.sangamo.com/press-releases/detail/365
Three current FDA Phase 1/2 trials, for $SGMO:
MPS I (Scheie, Hurler-Scheie and Hurler syndromes)
MPS II (Hunter syndrome)
Hemophilia B
https://www.biopharmcatalyst.com/company/SGMO
$SGMO is pre-clinical with 3 current Phase 1/2 studies with data due by March 2018.
But the pipeline is very wide and this will be an interesting stock in the 3-5 year time frame.
Congrats to everyone who got aboard this train in the $5 range!!!
http://www.sangamo.com/product-pipeline
SGMO RECEIVES PATENT 9771403 FOR HEMOPHILIA
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=sangamo&OS=sangamo&RS=sangamo
Adage Capital Partners GP LLC has filed a new 13G, reporting 5.56% ownership in $SGMO - https://fintel.io/so/us/sgmo and https://fintel.io/i/adage-capital-partners-gp-llc
* * $SGMO Video Chart 05-12-17 * *
Link to Video - click here to watch the technical chart video
This is probably 6/7 years away from any meaningful first approved product granting the trial is a success.
awesome guys congrats!! moving well on great news. this is what i like to see!
SGMO strong price action after hours. Big day tomorrow.
$SGMO - Sangamo teams up with Pfizer to develop gene therapies to treat hemophilia A; shares ahead 41% after hours
https://seekingalpha.com/news/3266158-sangamo-teams-pfizer-develop-gene-therapies-treat-hemophilia-shares-ahead-41-percent-hours#
Yup, congrats. We should see 8 tomorrow
Huge huge news!! Goes over $10 tomorrow
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |